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Abstract
Cerebrovascular (CV) dysfunction is emerging as a critical component of Alzheimer’s disease (AD), including altered CV
coverage. Angiogenic growth factors (AGFs) are key for controlling CV coverage, especially during disease pathology.
Therefore, evaluating the effects of AGFs in vivo can provide important information on the role of CV coverage in AD.
We recently demonstrated that epidermal growth factor (EGF) prevents amyloid-beta (Aβ)-induced damage to brain
endothelial cells in vitro. Here, our goal was to assess the protective effects of EGF on cognition, CV coverage and Aβ
levels using an AD-Tg model that incorporates CV relevant AD risk factors. APOE4 is the greatest genetic risk factor for
sporadic AD especially in women and is associated with CV dysfunction. EFAD mice express human APOE3 (E3FAD) or
APOE4 (E4FAD), overproduce human Aβ42 and are a well characterized model of APOE pathology. Thus, initially the
role of APOE and sex in cognitive and CV dysfunction was assessed in EFAD mice in order to identify a group for EGF
treatment. At 8 months E4FAD female mice were cognitively impaired, had low CV coverage, high microbleeds and
low plasma EGF levels. Therefore, E4FAD female mice were selected for an EGF prevention paradigm (300 μg/kg/wk, 6
to 8.5 months). EGF prevented cognitive decline and was associated with lower microbleeds and higher CV coverage,
but not changes in Aβ levels. Collectively, these data suggest that EGF can prevent Aβ-induced damage to the CV.
Developing therapeutic strategies based on AGFs may be particularly efficacious for APOE4-induced AD risk.
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Introduction
Cerebrovascular (CV) dysfunction is re-emerging as a crit-
ical component of Alzheimer’s disease (AD) (reviewed in
[36]). An unresolved issue is whether AD pathways induce
detrimental effects on CV length and the significance
for cognitive dysfunction. There is evidence of both
higher [7, 9, 13] and lower [18, 25, 29, 39] vessel
length and/or density (vessel coverage) in AD-patients
and mice (AD-Tg) that overproduce an important
contributor to AD progression; human amyloid-beta (Aβ).
Angiogenic growth factors (AGFs) are key for controlling
total vessel coverage. Therefore one approach for address-
ing issues in the field is evaluating the effects of AGFs on
AD-like pathology in vitro and in vivo. Positive in vivo
effects would also support future therapeutic research
focused on developing AGF-like drugs for AD. Despite the
promise of AGFs in models of stroke, published data in
AD models are limited and for some AGFs equally as con-
flicting as the data on CV coverage in AD [14, 40, 44, 47],
with the possible exception of the vascular endothelial
growth factor (VEGF). Peripheral VEGF administration
[58] or neuronal overexpression [44] improves cognition
and lowers Aβ levels in AD-Tg mice. Beyond these reports
review or opinion articles form the basis of our knowledge
of AGFs in AD [3, 26, 54]. We recently compared the
activity of the main AGFs at preventing Aβ-induced vessel
degeneration in vitro [31]. Epidermal growth factor (EGF)
prevented oligomeric Aβ42 (oAβ)-induced angiogenesis
deficits and disruption of preformed tubes. EGF was
also more protective than other AGFs, including VEGF.
The role of EGF in AD is unclear as both higher and
lower plasma EGF levels have been reported in AD
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patients [8, 17, 24, 30]. More recently low EGF levels
were reported to predict the conversion from amnestic
mild cognitive impairment to AD [33], supporting the
hypothesis that exogenous EGF will be protective in
AD-Tg mice. Contrastingly, there is improved cognition
in AD-Tg mice treated with the EGF receptor inhibitor
gefitinib [57]. Therefore, the primary goal of this study
was to assess the protective effects of EGF on cogni-
tion, CV coverage and Aβ-levels using an AD-Tg model
that incorporates CV relevant AD risk factors.
APOE4 is the greatest genetic risk factor for sporadic
AD, increasing risk up to 12-fold compared to APOE3
(reviewed in [34]). APOE4-induced AD risk is also
greater in females [2, 10, 41]. As APOE4 carriers also
often respond differentially in clinical trials it is im-
portant to identify novel mechanistic processes under-
lying APOE4-induced AD risk. Increasing evidence
indicates that APOE modulates CV morphology and
function (reviewed in [50]). In AD and AD-Tg models
APOE4 is associated with CV dysfunction including
basement membrane degradation and increased leaki-
ness [50]. Thus, incorporating human APOE4 in stud-
ies focused on the CV in AD is valuable.
EFAD mice express human APOE3 (E3FAD) or
APOE4 (E4FAD), overproduce human Aβ42 and are a
well characterized model of APOE modulated Aβ42
pathology [61]. We initially assessed the role of APOE
and sex in cognitive and CV dysfunction in EFAD
mice in order to identify a group for EGF treatment.
E4FAD female mice were cognitively impaired, had
high microbleeds, low CV coverage and low plasma
EGF levels at 8 months of age. Therefore, E4FAD
female mice were selected for an EGF prevention
paradigm (300 μg/kg/wk, 6 to 8.5 months). EGF pre-
vented cognitive decline and was associated with
lower microbleeds and higher CV coverage, but not
with changes in Aβ levels. Collectively these data
suggest that EGF can prevent Aβ-induced damage to
the CV. Developing therapeutic strategies based on




All protocols follow the UIC Institutional Animal Care and
Use Committee protocols. Breeding and colony mainten-
ance was conducted at the UIC as described in [61]. EFAD
mice express five Familial Alzheimer’s disease (FAD)
mutations (APP K670N/M671L + I716V +V717I and PS1
M146L + L286V) and human APOE3 (E3FAD mice) or
APOE4 (E4FAD mice) i.e. 5xFAD+/−APOE+/+. EFAD mice
utilized to start our breeding colonies were kindly provided
by Dr. M.J.Ladu.
Evaluation of cognitive and CV changes in EFAD mice at
8 months
Male (EFADM) and female (EFADF) E3FAD and E4FAD
mice at 8 months of age were sequentially assessed
(24 hrs. between tests) using the open field, novel object
recognition and spontaneous alternation (Y-maze) tests.
EFAD mice were then injected with sodium fluorescein
(NaFl, Sigma), anesthetized (100 mg/kg ketamine and
10 mg/kg xylazine), blood drawn via cardiac prick and
transcardially perfused with PBS containing protease in-
hibitors (Millipore). Right hemi-brains were dissected
into the cortex, hippocampus, and cerebellum and proc-
essed for NaFl extravasation. Left hemi-brains were
frozen over dry ice in cryomolds containing O.C.T com-
pound (Tissue-Tek), and stored at −80 °C until processing
for immunohistochemical (IHC) analysis. All investigators
were blinded for APOE genotype. n = 7 (E3FADM), 7
(E3FADF), 9 (E4FADM), 8 (E4FADF).
Treatment of female E4FAD mice with EGF
Six month old E4FADF mice were administered EGF
(Shenandoah, 300 μg/kg/wk) or vehicle control (water)
by intraperitoneal injection (i.p.) until 8.5 months. Body
weights were monitored prior to every injection. Mice
were sequentially assessed (24 hrs. between tests) using
the open field, novel object recognition, spontaneous al-
ternation (Y-maze) and novel arm entry (Y-maze) tests.
At the end-point behavior was further assessed using the
light-dark box and Morris water maze tests and food
consumption monitored over 24 h. 30 min prior to sac-
rifice mice were injected with EGF, dissected right hemi-
brains stored at −80 °C until homogenization and left
hemi-brains were stored for histological analysis. NaFl
extravasation was not conducted on the EGF or VC
treated E4FADF mice to enable biochemical analysis of
Aβ, apoE and EGF levels in brain homogenates. For all
analysis investigators were blinded for treatment. n = 8
per group.
Behavioral analysis
Behavioral analysis was conducted in the mouse dark
cycle, tracked in real time by an overhead camera and
videos analyzed using the ANY-Maze software.
Open field. Mice were placed in the center of a white
box (l38.5xw30xh30 cm) and allowed to freely move for
10 min. The distance traveled and average speed were
measured.
Novel object recognition was conducted as described
in [62] with slight modifications. On day 1, mice were
habituated in a white testing chamber (38.5x30x30 cm)
for 20 min. On day 2, mice were placed in the same
testing chamber that contained two identical objects for
7 min, returned to their home cage for 1 hr and placed in
the testing chamber with a familiar and a novel object for
Thomas et al. Acta Neuropathologica Communications  (2016) 4:111 Page 2 of 14
7 min. Time spent with each object and the preference
index (ratio of time spent with the novel object divided by
total investigation time for both objects) were calculated.
Mice that did not investigate both objects for longer than
5 s were not included. Data for one E3FADF and one
E4FADF were removed (Fig. 1) based on the exclusion
criteria.
Spontaneous alternation (Y-maze)
Mice were placed in one arm of a Y-maze apparatus
(38.5x8x13 cm, spaced 120° apart) allowed to explore for
7 min and the sequence of arm entries were recorded.
Spontaneous alternation was calculated as the number
of alternations (entries into three different arms con-
secutively) divided by the total possible alternations (the
number of arms entered minus 2) and multiplied by 100.
Novel arm entry (Y-maze)
Mice were placed into the maze (plus extra-maze cues)
with one of the arms blocked for 10 min, returned to
the home cage for 60 min and placed back in the maze
with access to all three arms for 5 min. The time spent
in the novel arm was calculated.
Light-dark box
The light-dark box (21x42x25 cm) consists of two cham-
bers with an opening in-between (7.3 cm): the light
chamber is brightly illuminated with white walls (66.6 %
of the box) the dark chamber comprises of dark walls
(33 %). Mice were placed into the light side and allowed
to move freely for 5 min. The time spent in each cham-
ber was recorded.
Morris water maze (MWM) was conducted as
described in [35] with slight modifications in three
phases. The circular pool was 120 cm in diameter and
50 cm tall, and the circular escape platform was 10 cm
in diameter. The pool was filled with water containing
non-toxic tempera paint (maintained at 25 °C) to 10 cm
below the top rim and divided into equal-sized imagin-
ary quadrants. Extramaze cues were placed in the four
corners for spatial orientation. A single mouse was in
the pool for each testing phase/session. MWM testing
was comprised of three phases. (a) Visual Cue phase.
Mice were trained over the course of 2 days to locate a
flagged hidden platform (60s trial time, four trials each
day with a 20 min inter-trial interval (ITI)). (b) Acquisi-
tion phase. After 2 days, mice were trained for 5 days
Fig. 1 Cognitive and cerebrovascular dysfunction in E4FADF mice. a E4FADF mice are cognitive impaired when assessed by novel object
recognition and spontaneous alternation. b There are higher NaFl levels in the cortex (Cx) and hippocampus (Hp) of E4FADF mice after i.p
injection. n = 7(E3FADM), 6 (E3FADF), 9 (E4FADM), 7 (E4FADF). c Prussian blue staining (microbleeds) is higher in the Cx and Hp of E4FADF mice
when assessed by IHC analysis. n = 7 (E3FADM), 7 (E3FADF), 9 (E4FADM), 8 (E4FADF). Data expressed as mean +/− S.E.M. *p < 0.05 by two-way
ANOVA and Tukey’s post hoc comparisons. #p < 0.05 by two-way AVOVA followed Fisher’s LSD test
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(60s trial time, four trials each day with a 20 min ITI) to
locate the position of the hidden platform (remains on
the hidden platform for >2 s). During the visual cue and
acquisition phases the mouse’s entry quadrant varied but
the platform location remained constant. Latency to find
the platform (s) was measured. (c) Probe trial. 1 h
following the final acquisition trial, a single 60s probe
trial was conducted with the platform removed. The la-
tency to the target area (i.e., where platform was located
during acquisition phase) and the time spent in the tar-
get quadrant were calculated.
Sodium fluorescein extravasation
Mice were injected i.p. (200 μl) with 2 % NaFl, sacrificed
after 30 min and tissue harvest conducted as described
above. Dissected brain regions were weighed, homoge-
nized in PBS, suspended in equal volumes of 60 % tricho-
loroacetic acid, then vortexed and centrifuged (18,000 ×
g,10 min, 4 °C). Fluorescence levels were measured using
a microplate reader (SpectraMax i3x, Molecular Devices)
and cleared volumes calculated as: [1/plasma levels (fluor-
escence units/μl) x total brain fluorescence]/brain weight.
Biochemical analysis
Dissected brains were weighed and sequentially ex-
tracted using the 3-step extraction protocol as de-
scribed in [61].
Protein quantification
Total protein in Tris-buffered saline (TBS) and neu-
tralized formic acid (FA) extracts was quantified using
the Ready to Use Bradford Reagent (Bio-Rad) and for
TBS-Triton X100 (TBSX) extracts the BCA Protein
Assay Kit (Pierce).
For western blot analysis of TBS-X fractions protein
(20 μg) was separated on 4–12 % Bis-Tris gels (Invitrogen)
and transferred onto low-fluorescence PVDF membranes.
Membranes were blocked (1 hr. room temperature) with
5 % non-fat milk in TBS containing 0.1 % Tween 20
(TBST), then incubated (4 °C, overnight) with primary
antibodies against post synaptic density protein (PSD-95,
1:1000, Cell Signaling), synaptophysin (1:1000, Cell Signal-
ing), the EGF receptor (1:100, Santa Cruz Biotechnology)
or actin (1 hr. room temperature, 1: 20,000, Cell Signaling)
in TBST with 5 % bovine serum albumin (BSA). Mem-
branes were incubated in secondary antibodies (Jackson
Immunoresearch) with TBST wash (3X5min) in between
steps and imaged using an Odyssey ® Fc Imaging System.
Image J was utilized to quantify actin normalized proteins.
ELISA
ApoE and Aβ42 (Life Technologies) levels were measured
in the TBS, TBSX and FA extracts, and oAβ (Biosensis) in
the TBS extracts. The apoE ELISA utilizes α-apoE (1:2000,
Millipore) capture and α-apoE biotin-gt (1:5000, Merid-
ian) detection antibodies as described in [48]. EGF levels
were measured in the plasma and TBS extracts (R&D).
Histological analysis
Frozen brains were sectioned at 12 μm and fixed using
10 % Neutral Buffered Formalin (Sigma). Nine nonadja-
cent sections (108 μm apart) were utilized for quantifica-
tion per animal.
Prussian blue stain
Slides were hydrated in distilled water, submerged in
equal parts of potassium ferrocyanide and hydrochloric
acid (30 min), rinsed in distilled water (1 min) and
counter-stained with Nuclear Fast Red (5 min, Rowley
Biochemical Institute J-606-3). After another wash in
distilled water (1 min) slides were dehydrated (50, 75,
95, & 100 % alcohol series), cleared in xylene and
mounted. Slides were scanned at 20x magnification on a
Leica Aperio AT2 scanner. The resulting image files
were loaded into Aperio eSlide Manager (version
12.3.1.6002) and regions of interest were drawn using
Aperio ImageScope (version 12.3.2.5030) around the
cortex and hippocampus in separate layers and scored
using Definiens Tissue Studio (version 4.2) using the
‘Marker Area’ solution. The solution was modified to
identify Nuclear Fast Red and quantify the percent of tis-
sue positive for Prussian blue (indicating microbleeds) in
each of the brain regions. Data for multiple sections per
brain were combined.
CD31 immunostain
Sections were incubated in 0.3 % hydrogen peroxide
(30 min), blocked in 10 % rat-serum (2 hr) and incu-
bated with a rat anti-mouse CD31 antibody (MEC13.3,
BD Bioscience 1:10, 4 °C overnight). Sections were
stained with the Vectastain ABC Kit according to the
manufacturer’s protocol (Vector), dehydrated through
alcohol series and cleared in xylene with PBS (3X5min)
washes in between steps. Slides were digitally scanned
and traced (deep layer cortex and subiculum) as for
Prussian blue. The Aperio microvessel algorithm (ver-
sion 11.2.0.780) was optimized to quantify the percent
area of tissue and density occupied by blood vessels per
brain region on the slide.
Laminin and Aβ stain
Slides were incubated in 60 % FA (8 min), sections perme-
abilized with TBS containing 0.25 % TBSX (3X5min) and
blocked with 5 % BSA in TBSX (2 hr). Slides were incu-
bated with anti-Aβ (MOAB-2, mouse IgG2b, 1:400 dilu-
tion, Biosensis) and anti-laminin (Rabbit, 1:400 dilution,
Abcam) antibodies in TBS containing 2 % BSA and 0.10 %
Triton X-100 (4 °C, overnight) in a humidified chamber.
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Slides were washed (3x5min in TBSX), incubated with
Alexa fluorophore-conjugated secondary antibodies (Alex-
aFlour 750 anti-rabbit, Alexafluor 350 anti-mouse IgG2b)
diluted 1:200 in TBSX containing 2 % BSA (2 hr) and
washed in TBSX (3X5min) followed by TBS (1x5min).
Mosaic and single images were captured on a Zeiss Axio
Imager M1 under identical capture settings at 20x magni-
fication. Converted images were thresholded equally to
diminish background signal (NIH ImageJ software). Iden-
tified objects after thresholding were scanned to validate
either vessel or Aβ staining. Mosaic images were outlined
for the subiculum, deep layer or full cortex and quantified
(Analyze Particles function).
Thioflavin-S stain
Slides were incubated in filtered 1 % aqueous Thioflavin-
S (5 min, Sigma) protected from light, dehydrated in
70 % ethanol (2X5min) and washed in PBS (2X2min).
Mosaic images were captured as for laminin and
MOAB-2 staining at 10X magnification. Plaques were
evaluated for total number and percent area covered
(total Thioflavin-S immunoreactivity/ROI) using Image J
as described in [61].
Claudin 5 stain
A representative slide from EGF or VC treated E4FADF
mice was stained according to the protocol described for
Laminin staining, using an anti-claudin 5 antibody (1:20,
Santa Cruz Biotechnology) and AlexaFlour 647 anti-
rabbit secondary antibody (1:200).
Statistical analysis
All data are presented as mean +/−S.E.M, and were ana-
lyzed using two-way ANOVA followed by either Tukey’s,
Fisher’s LSD or Sidak’s post hoc comparisons or using
Student’s t-test, as specified in the figure legends using
GraphPad Prism version 6.
Results
Female E4FAD mice are cognitively impaired at 8 months
of age
EFAD mice overproduce Aβ42 (via 5XFAD mutations)
APP K670N/M671L + I716V + V717I and PS1 M146L +
L286V) and express human APOE3 (E3FAD mice) or
APOE4 (E4FAD mice). In EFAD mice Aβ pathology is
prevalent in the hippocampal formation, primarily the
subiculum, and in the deep layers of the frontal cortex
[61]. Published data demonstrate that by 7 months
soluble Aβ and extracellular plaque levels follow the order:
E4FAD female (E4FADF) > E3FAD female (E3FADF) =
E4FAD male (E4FADM) > E3FAD male (E4FADM) [12].
Specific for the CV, cortical microbleeds are also reported
as highest in E4FADF mice [12]. In order to select a sex
and genotype of EFAD mice for treatment with EGF, it
was important to identify the association among cognitive
decline and CV dysfunction. Initially, cognitive impair-
ment was assessed in E3FADM, E3FADF, E4FADM and
E4FADF mice at 8 months of age. E4FADF mice were cog-
nitively impaired compared to all other groups when
assessed by both novel object recognition and spontaneous
alternation (Y-maze) tests (Fig. 1a, two-way AVOVA
followed by Tukey’s post-hoc analysis). Indeed, E4FADF
mice performance was ~35 % lower in novel object
recognition and ~30 % lower in the spontaneous alter-
nation test.
Higher CV leakiness and lower CV coverage in E4FADF
mice
To determine the role of APOE and sex in CV leakiness,
brain levels of NaFl were assessed after i.p. injection
(Fig. 1b). NaFl levels were significantly higher in the
cortex of E4FADF mice compared to E3FADM and
E4FADM mice and were higher in hippocampus com-
pared to all other groups (two-way AVOVA followed by
Tukey’s post-hoc analysis). NaFl levels were also higher
in E3FADF mice compared to EFADM mice (two-way
AVOVA followed by Tukey’s post-hoc analysis) in the
hippocampus, whereas in the cortex these effects were
only significant by two-way AVOVA followed by Fisher’s
LSD test. Prussian blue staining was conducted to assess
microbleed coverage as a complimentary measure of CV
leakiness (Fig. 1c). In the cortex the area of microbleed
coverage followed the order E4FADF > E3FADF > E4FADM
=E3FADM (Fig. 1c, two-way AVOVA followed by Tukey’s
post-hoc analysis). In general cortical microbleed coverage
was 20-fold higher in E3FADF mice and 55-fold higher in
E4FADF mice compared to EFADM mice. In the hippo-
campus microbleed coverage was only higher in E4FADF
mice when assessed by two-way AVOVA followed by
Fisher’s LSD test.
Next, laminin (basement membrane protein)-Aβ co-
staining was conducted as an indication of total vessel
coverage. Visually laminin staining appeared lower in dee-
per layers of the frontal cortex and the subiculum in
EFADF mice compared to males, an effect particularly pro-
nounced in E4FADF mice (Fig. 2a and b). When quanti-
fied for % area covered (Fig. 2c), no differences were
observed for laminin staining among the groups for the
whole cortex. In the deep layer cortex laminin staining
followed the order: E4FADM/E3FADM>E3FADF>E4FADF
(two-way AVOVA followed by Tukey’s post-hoc analysis).
Data for the subiculum followed the same pattern.
Overall, laminin staining was 10 % lower in E3FADF
mice and 20 % lower in E4FADF mice in the deep
layer cortex and subiculum compared to EFADM
mice. Extracellular Aβ levels followed the order
E4FADF > E4FADM = E3FADF > E3FADM (Fig. 2d).
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Plasma EGF levels are lowest in EFADF mice
EGF plays a key role in controlling total vessel coverage
and a recent report indicates that low plasma EGF pre-
dict the conversion from MCI to AD [33]. We therefore
measured plasma EGF levels in EFAD mice (Fig. 2e).
E3FADM mice had higher plasma EGF levels than all
other groups (2-way ANOVA, followed by Tukey’s post-
hoc comparison). There was also a trend of higher EGF
plasma levels in E4FADM mice compared to EFADF
mice, which was significant by Student’s t-test. One
Fig. 2 Lower laminin coverage in E4FADF mice. a–c Laminin (basement membrane protein) staining is lower in E4FADF mice in brain regions of
extracellular Aβ pathology: the subiculum and deep layers of the cortex (Dl-Cx) but not significantly different in the full-length cortex (Fl-Cx)
between groups when assessed by IHC analysis. Further, E3FADF mice exhibit lower staining than E3FADM mice. d Extracellular Aβ levels are
highest in E4FADF mice (IHC analysis using the antibody MOAB2). e Plasma EGF levels are low in EFADF mice. n = 7(E3FADM), 7 (E3FADF), 9
(E4FADM), 8 (E4FADF) when assessed by ELISA. Data expressed as mean +/− S.E.M. *p < 0.05 by two-way ANOVA and Tukey’s post hoc comparisons.
#p < 0.05 by Student’s t-test
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caveat is that NaFl injection may have modulated plasma
EGF levels in the EFADF mice, in an APOE genotype
specific manner.
Collectively, these data support that 8 month old
EFADF mice are cognitively impaired, have low CV
coverage, high CV permeability and low plasma EGF
levels. Therefore E4FADF mice were selected for treat-
ment with EGF in a prevention paradigm.
EGF prevents cognitive decline in E4FADF mice
Our overarching goal was to test EGF in a prevention
paradigm based on our recent data that EGF prevents
Aβ-induced disruption of angiogenesis and degeneration
of preformed tubes in vitro [31]. E4FADF mice were
treated with EGF (300 μg/kg/wk) by i.p. from 6 to
8.5 months and tested by a battery of tests for cognitive
ability (Fig. 3a). 300 μg/kg/wk was selected as a low dose
that does not promote cancer or overt signs of toxicity
in mice [6]. EGF induced a profound protective effect on
cognitive decline in E4FADF mice compared to the
vehicle control (VC). When assessed by novel object
recognition (Fig. 3b), spontaneous alternation (Fig. 3c, Y-
maze) and novel arm entry (Fig. 3d, Y maze) the VC
control groups progressively declined in cognitive ability
from 6 to 8 months (two-way ANOVA followed by
Sidak’s post hoc comparisons which takes into account
same animal re-testing). In contrast, no age-dependent
decline was observed for EGF treated mice. At the mid-
point EGF treated mice performed 46 % higher in the
novel object recognition and 37 % higher in the number
of spontaneous alternations performed (Y-maze) com-
pared to the VC. At the end-point, EGF treated mice
performed ~58 % higher in novel object recognition and
spontaneous alternation and spent 477 % longer in the
novel arm test (Y-maze).
Cognitive ability was further dissected at the end-point
in the Morris water maze test (Fig. 3e). In the acquisi-
tion phase EGF (day 1 vs 5 and 2 vs 5 were significant)
and VC treated mice (day 1, 3 and 4 vs day 5 were
significant) learned the location of the platform by day 5.
On day 3 the EGF treated mice located the platform
earlier than the VC, indicative of improved learning. In
the probe trial (Student’s t-test) EGF treated mice lo-
cated the previous platform area with a lower latency
time (VC = 38.6 s, EGF = 5.15 s) and spent a longer time
in the target quadrant (VC = 11.6 s, EGF = 30.9 s). EGF
did not modulate levels of the pre-synaptic protein
synaptophysin in the cortex or hippocampus (Fig. 3f ).
However, consistent with the behavior data levels of the
postsynaptic protein PSD95 were higher in the cortex
(35 %) and hippocampus (50 %) in EGF treated mice
(Fig. 3g, Student’s t-test). Thus, in a prevention paradigm
EGF-induces a beneficial effect on cognition and post-
synaptic neuronal markers.
EGF treatment had no effects on locomotion, food intake,
anxiety-like behavior and brain EGF levels
A potential confounding factor for the beneficial effects
of EGF on cognition is whether EGF modulates anxiety-
like behavior. VC treated mice remained steady in
weight until week 4 (7 months old) where they gained
~5 % and then remained at the same weight for the rest
of the study. EGF treated mice lost ~ 7 % in weight at
week 4 and then remained steady (Fig. 3h). The changes
in bodyweight were not related to general locomotion,
as in the open field test there were no differences
between EGF and VC treated mice (Fig. 3i, two-way
ANOVA followed by Sidak’s post hoc). At the end-point
(8 months) there were no differences in food intake
(Fig. 3j over 24 hrs, Student’s t-test) or anxiety like
behavior as assessed in the light-dark box test (Fig. 3k,
Student’s t-test). The improved cognition with EGF com-
pared to the VC was not related to general locomotion
or anxiety like effects.
EGF can exert pleiotropic actions on many cells within
the brain and it was important to determine whether
brain EGF levels were increased after treatment. 30 min
prior to sacrifice mice were treated with EGF and levels
assessed by ELISA in the plasma (Fig. 3l, Student’s t-
test), cortex, and hippocampus (Fig. 3m). Plasma EGF
levels were ~4 pg/ml in VC treated mice and ~ 250 ng/
ml after EGF treatment. There were no differences in
hippocampal or cortical EGF levels between VC and
EGF treated mice. In addition, when assessed by western
blot analysis EGF receptor levels were not altered by
EGF treatment in the hippocampus or cortex of E4FADF
mice (Fig. 3n and Additional file 1: Figure S1d). How-
ever, we cannot exclude that there were cell-specific
changes in EGF receptor levels after treatment.
Therefore, the beneficial effects of EGF on cognition
were likely mediated by peripheral rather than CNS
levels of EGF.
EGF treatment lowers microbleeds and increases CV
coverage compared to the VC
Next the effect of EGF on microbleed coverage was
assessed. Microbleeds were lower in EGF treated mice
compared to the VC. The percent area covered by
microbleeds was 55 % lower in the cortex and 66 %
lower in the hippocampus in the EGF treated group
(Fig. 4a, Student’s t-test). A sub-goal of this study was to
determine whether EGF modulates CV coverage in vivo.
Thus laminin-Aβ co-staining was conducted (Fig. 4b,
Student’s t-test). Visually EGF treated mice had a higher
area covered by laminin staining than the VC in the deep
layers of the cortex and the subiculum (Fig. 4b–c).
Quantification of the laminin stain validates this finding
as the percent area covered was 15 % (deep layer cx)
and 25 % (subiculum) higher than the VC (Fig. 4d). To
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further dissect the role of EGF on CV coverage, quanti-
tative IHC was conducted for CD31, a brain endothelial
cell marker. In EGF treated mice CD31 coverage was
36 % higher in the deep layer cortex and 90 % higher in
the subiculum compared to the VC (Fig. 4f, Student’s t-
test). IHC staining for claudin 5 positive vessels revealed
a similar staining pattern as for CD31 (Additional file 1:
Figure S1a). Vessel coverage (% area covered) is a com-
bination of density and length. There were no changes
in laminin (Additional file 1: Figure S1b) or CD31 dens-
ity (Additional file 1: Figure S1c) between VC and EGF
treated mice. These data support that EGF prevents the
lowering of CV length in E4FADF mice. It is important
to note that distinguishing CV length and density with
the IHC techniques utilized here is not straightforward.
The optimal technique for assessing length and density
entails three dimensional reconstruction of larger brain
volumes with read read-outs for multiple parameters in-
cluding branching points, major nodes, vessel length
between nodes and the distribution of vessel lengths.
Therefore, we prefer the term CV coverage for the pur-
pose of this manuscript.
EGF has no effect on Aβ levels
As EFAD mice are a model of APOE modulated Aβ
levels and induced dysfunction, we next assessed
whether EGF modulates Aβ levels. There were no differ-
ences in extracellular amyloid (ThioS, Fig. 5a, Student’s
t-test) or extracellular Aβ (Fig. 4b–e and Fig. 5b,
Student’s t-test) staining between the EGF and VC
treated mice. EGF also had no effect on soluble, deter-
gent soluble or insoluble Aβ42 levels in the cortex or
hippocampus when assessed biochemically (Fig. 5c and
d). More recent data suggest that soluble oligomeric Aβ
is more AD-relevant than extracellular Aβ, however EGF
treatment did not modulate soluble oligomeric Aβ levels
(Fig. 5e, Student’s t-test). Further, there were no differ-
ences in apoE levels between EGF and VC treated mice
Fig. 3 EGF prevents cognitive deficits in E4FADF mice. a Experimental design for EGF prevention paradigm in E4FADF mice. EP, end-point; MP,
mid-point; EP, end-point; OF, open field; SA, spontaneous alternation; NOR, novel object recognition; NAE, novel arm entry; LD, light-dark box;
MWM-VC, Morris water maze visual cue phase; MWM-AP, Morris water maze acquisition phase; MWM-PT; Morris water maze probe trial. b–d EGF prevents
cognitive decline when assessed by NOR, SA and NAE. Dashed line represents no preference (novel object) or chance alternation (spontaneous alternation).
e EGF treatment improves performance in the Morris water maze test (EP). Representative track plots of probe trial is based on latency to previous platform
area. f Synaptophysin levels are the same in EGF and VC treated mice when assessed by western blot analysis. g PSD-95 levels are higher in EGF treated
E4FADF mice (western blot analysis). h Body weight decreased at 4 weeks but remained constant until 10 weeks with EGF treatment. i–k EGF treatment
did not modulate performance in open field, had no effects on food intake (over 24 hrs at EP) and did not change performance in the light-dark box test.
l,m EGF treated mice had higher plasma but not brain levels of EGF (ELISA). n There were no changes in EGF receptor levels in the cortex or hippocampus
after EGF treatment (western blot). n= 8 per group for a–m and n= 6 for n. Data expressed as mean +/− S.E.M. *p< 0.05 by 2-way ANOVA and Sidak’s
post-hoc analysis (B-E, G and H). *p< 0.05 by Students t test (E probe trial, F, I-K)
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in any extracted fractions (Fig. 5f–g). Therefore, the
protection of EGF on cognitive and CV length was
unlikely to be mediated by lowering Aβ42 or chan-
ging apoE levels.
Discussion
AGFs play a key role in controlling total vessel coverage,
especially during disease pathology. In AD research the
effects that AFGs will induce on AD-like pathology in
vivo is a controversial topic. Previously we have demon-
strated that EGF can prevent oligomeric Aβ-induced dis-
ruption of total vessel length in vitro. Here our goal was
to determine whether EGF prevents cognitive and CV
dysfunction in an AD-Tg model that incorporates hu-
man APOE and high Aβ levels, both of which are im-
portant for AD and CV function. We demonstrated that
E4FADF mice are cognitively impaired, have higher CV
leakiness and lower vessel coverage than other groups at
8 months and also had low plasma EGF levels. Critically,
we report for the first time that cognitive performance
and vessel coverage was higher in E4FADF mice treated
with EGF in a prevention paradigm. These data support
further research on the development of AGF-based ther-
apies for AD.
Sex and APOE4-induced cognitive and CV dysfunction in
EFAD mice
Our data support that sex and APOE4 impact cognition
and CV dysfunction in EFAD mice. In E4FADF the CV
dysfunction was accompanied by cognitive dysfunction. In
E3FADF mice CV leakiness was higher, CV coverage lower
and plasma EGF levels lower compared to EFADM mice.
Fig. 4 EGF prevents cerebrovascular dysfunction in E4FADF mice. a Microbleeds are lower in EGF treated mice (IHC analysis). b–d Laminin
staining is higher in the deep layer cortex and subiculum in EGF treated mice (IHC analysis). e, f CD31 staining is higher in the deep layer cortex
and subiculum after EGF treatment (IHC analysis). n = 8 per group. Data expressed as mean +/− S.E.M.*p < 0.05 by Students t test
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As there were no changes in cognitive function in
E3FADF mice compared to EFADM mice, the CV effects
may represent early changes that later manifest as cogni-
tive decline. These findings raise important questions on
the relationship to human and other in vivo data and the
mechanisms underlying sex-induced APOE modulated
changes in cognition and CV coverage.
In AD patients APOE4-induced risk is greater in
females [2, 19, 20, 41, 45] consistent with our finding
that E4FADF are cognitively impaired compared to all
other groups tested at 8 months. In partial contrast a
few reports have demonstrated impaired cognition in
male APOE4-TR mice (which do not overproduce hu-
man Aβ) compared to APOE3-TR mice [46, 56]. How-
ever, in a separate detailed analysis of APOE-TR mice
the deficits in memory were primarily observed in
female APOE4-TR mice [21]. Data on CV coverage is
lacking in human patients stratified for sex and APOE
genotype. In 9 and 12 months old APOE-TR mice lower
microvessel coverage has been demonstrated [1, 4],
although the effect of sex is unclear. A detailed compari-
son of EFAD and APOE-TR mice may reveal whether
Aβ accelerates the APOE4 and female sex driven cognitive
deficits and changes in CV coverage. In AD microbleeds
are associated with male sex, higher blood pressure, lower
CSF Aβ42 and APOE4 [5]. These data contrast with the
female bias observed in EFAD mice [12, 20]. A confound-
ing factor is whether additional AD-risk factors are
present in male AD patients assessed for microbleeds. For
example, level of exercise, hypertension, hyperglycemia,
hyperinsulinemia and insulin resistance observed in type 2
diabetes all modulate AD-risk and the CV. Further,
men are at a higher risk of developing cardiovascular
events. The controlled laboratory conditions utilized
here may be more relevant for studying the interaction
among sex, APOE and Aβ in the absence of additional
risk factors. Further research could focus on introdu-
cing additional AD-risk factors in vivo.
Fig. 5 EGF has no effect on Aβ levels. a, b ThioS plaque and extracellular Aβ levels were the same in EGF and VC treated E4FADF mice (IHC
analysis). c, d When assessed biochemically, EGF also had no effect on soluble, detergent soluble or insoluble Aβ42 levels in the cortex of
hippocampus (ELISA). e Soluble oAβ levels were unaffected by EGF treatment (ELISA). f, g ApoE levels were unaffected by EGF treatment (ELISA).
n = 8 per group. Data expressed as mean +/− S.E.M. Data non-significant by Students t test
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Females are at a higher risk for AD, which is often at-
tributed to the loss of sex hormones during the meno-
pause [45]. In the mouse model utilized here, with no
ovariectomy, there may be inherent sex-differences that
modulate CV and AD-like pathology. Extracellular Aβ
levels from highest to lowest were: E4FADF > E4FADM
= E3FADF > E3FADM consistent with previous reports
[12, 51, 61]. Thus, higher levels of Aβ in E4FADF mice
could induce or accelerate signaling cascades that cause
CV degeneration. As described above CV coverage is
lower in APOE4-TR mice which supports an acceler-
ation rather than primary causation of CV deficits
caused by Aβ. The low CV coverage and EGF levels in
E3FADF mice compared to E4FADM mice are not asso-
ciated with higher Aβ levels, supporting an Aβ-level in-
dependent mechanism. Females prior to menopause are
at an increased risk for some autoimmune diseases and
there are a number of proposed mechanisms underlying
these effects [28]. For example, females may have a
greater immune/inflammatory response in the periphery
and the brain [28]. Although potentially beneficial for
fighting infection an enhanced or prolonged immune/in-
flammatory response in females may predispose, or po-
tentiate Aβ-induced direct and indirect damage to the
CV. It is also noteworthy that lower vessel coverage was
associated with low plasma EGF levels in EFADF mice.
Low EGF plasma appear to increase the conversion of
MCI to AD [33] but a sex bias has not been reported.
Early reports in mice have demonstrated lower plasma
EGF levels in females compared to males [42]. Further,
plasma EGF levels in female mice are altered by the cir-
cadian rhythm, pregnancy, [53] and are increased with
testosterone treatment [52]. Although 17-β estradiol is
protective against brain endothelial damage in vitro [38],
perhaps the male sex hormones exert a greater protect-
ive effect. A possibility is that low EGF levels in females
result in lower protection of the CV to damage in AD,
which is potentiated by APOE4 and accelerated by Aβ.
Speculating further, the low plasma levels of EGF in
female mice may be indicative general growth factor
suppression or a form of accelerated aging/senescence.
The effects of APOE in AD are multifactorial, complex at
the structural and mechanistic level and an area of intense
research (reviewed extensively in [23, 34, 37, 43, 55, 59]).
On a simplified level apoE4 can effect CV length through
modulating Aβ levels and via signaling to cells at the
blood-brain barrier (BBB) to alter Aβ-dependent and inde-
pendent effects. As discussed, there are higher Aβ levels in
APOE4 AD patients and E4FADF mice in this study. Aβ
can cause vessel disruption by directly signaling to brain
endothelial cells and indirectly via neuronal dysfunction
and activation of astrocytes, microglia and pericytes.
ApoE also signals to different cells types in the brain
to disrupt vessel length. In astrocytes and microglia
apoE4 is associated with a detrimental stress-induced
(including Aβ) neuroinflammatory response [49]; media-
tors described as inflammatory can affect brain endothelial
function (e.g. cytokines, matrix metalloproteases). In peri-
cytes apoE4 is less effective at suppressing motility [15]
and preventing MMP9 production [4, 22], both of which
disrupt total vessel length. ApoE4 also directly disrupts
brain endothelial cell tight junctions and effects peripheral
lipid metabolism to cause brain endothelial dysfunction.
Overall, the female sex-induced, APOE4 modulated, Aβ
accelerated changes in homeostatic signaling at the CV
may ultimately converge to predispose and/or amplify
stress-induced brain endothelial damage. Our ongoing
studies are focused on delineating the role of APOE, aging,
sex and peripheral risk factors on CV length.
EGF prevents cognitive and CV dysfunction in E4FADF
mice
An important finding here is that EGF prevented CV
dysfunction in E4FADF mice. These data are in agree-
ment with the lower EGF plasma levels observed in
humans and the beneficial effects of EGF in models of
stroke and traumatic brain injury. In contrast improved
cognition after blocking the tyrosine kinase activity of
the EGF receptor (EGFR) with gefitinib has been re-
ported in drosophilia and AD-Tg mice [57]. Aside meth-
odological differences that commonly impact data (e.g.
mouse model, time of treatment), the specificity of gefi-
tinib for the EGFR has been drawn into question.
Recently, gefitinib was demonstrated to antagonize a
number of G-protein coupled receptors including adre-
noreceptors, chemokine receptors, histamine receptors
and other neuronal receptors [60]. Gefitinib is reported
as a brain penetrant and therefore its beneficial effects
in AD-Tg mice could be mediated by non-EGFR targets
that play a role in AD-like pathology.
As EGF induced a pronounced effect on preventing
cognitive decline in E4FADF mice, it is important to
consider potential mechanisms of action. Our data sup-
port that the primary mode of action is not on cells
within the brain, since brain EGF levels were not altered
after EGF treatment. One caveat is that the technique
used to measured EGF (ELISA of whole cortex or hippo-
campus) may have failed to detect regional high concen-
trations of EGF. Further, EGF did not modulate Aβ
levels unlike VEGF in AD-Tg mice [58]. Although VEGF
lowers Aβ levels in slice cultures [11] a role for EGF in
this process has not been assessed. As EGF did not
change Aβ levels, one hypothesis is that EGF acts
directly on brain endothelial cells to prevent disrupted
signaling induced by the interactive effects of female sex,
APOE4 and Aβ in E4FADF mice. This is consistent with
our in vitro data [31], the beneficial effect of EGF in
wound healing, the promotion of angiogenesis in cancers
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that produce high EGF levels or that contain a mutation
in erbb2 (a dimerization receptor partner of the EGFR),
the protective effect of EGF-induced angiogenesis in
stroke models and the general protective function of
EGF in epithelial tissue (reviewed in [16]). Further, during
the course of treatment EGF may have prevented a loss of
key proteins involved in the homeostatic functions of brain
endothelial cells, prior to vessel degeneration. For example
key proteins involved in the nutrient transport/signaling
molecule supply, waste product removal and efflux/meta-
bolic/structural barrier functions of brain endothelial cells.
For microbleeds a key question remains on whether EGF
prevented global leakiness deficits in capillaries (e.g. via
preventing tight junction changes or basement membrane
degradation) and/or dysfunction at the post capillary ven-
ule level (the site of cellular trafficking).
An alternative hypothesis is that EGF activated recep-
tors outside of brain endothelial cells in the CNS and/or
the periphery to cause functional effects that prevent
changes in CV coverage. For example, subtle increases
in brain EGF levels may induce a beneficial response in
pericytes, astrocytes, microglia or neurons to modulate
levels of soluble molecules that maintain CV length. In
the periphery EGF can signal in cells of virtually every
organ in the body [15] and is associated with changes in
metabolism and insulin signaling, both of which may
protect the CV. An indicator of the peripheral effects is
the lower body weight in EGF treated mice. EGF may
also prevent cognitive decline independent of any CV
changes through the same CNS and peripheral processes
described above, in addition to promoting neurogenesis.
Our data provide the basis for further studies dissecting
if brain endothelial cells are the primary target of EGF.
CV length and AGFs as potential therapeutic targets in AD
What do the data mean in the context of CV length in
AD and therapeutic options for AD patients? There is no
clear in vitro or in vivo consensus on whether there is
higher or lower CV in AD. One proposal is that lower CV
density contributes to AD progression by disrupting cere-
bral blood flow and the complex transport and metabolic
systems of the CV [18, 25, 29, 39]. The counter argument
is that AD-pathways induce angiogenesis, causing hyper-
sprouting and tight junction disruption, which increase
CV permeability [7, 9, 13]. Traditional angiogenic signal-
ing, typically observed over the short-term is likely not ap-
plicable to a chronic neurodegenerative condition such as
AD. Pathological angiogenesis, described as the angiogen-
esis hypothesis [3] may be more applicable for AD: AD-
processes not only cause direct vessel degeneration but
also induce signaling cascades consistent with increased
angiogenesis, however there is a failure to complete mat-
uration and vessel formation. AD-risk factors both in the
CNS and periphery could predispose and amplify the
disrupted angiogenic signaling in brain endothelial cells.
There is a drive to develop novel strategies for AD as
an alternative or complimentary approach for Aβ or tau-
based therapeutics. AGF-like drugs may meet this
criteria, yet are frequently overlooked in drug develop-
ment programs. Indeed, an alternative focus is proposed
of using therapeutics to block angiogenesis-like pro-
cesses [54]. Our data with EGF and published data with
other factors that increase total vessel coverage support
an alternative approach [3, 26, 27, 32], which is to
stabilize brain endothelial cells and maintain or increase
vessel length. Further research is required to fully dissect
the use of AGF-based treatments for AD. Key research
areas include the potential for AGFs to reverse AD-like
pathology in vivo, distinguishing CV versus peripheral
effects and dissecting whether EGF-like molecules act
on cells within the brain (i.e., would a brain penetrant
AGF-like drug or treatment protocol be more efficacious
than non-CNS penetrant). Further research is needed to
address the concerns that agonists for AGF receptors
could increase cancer risk. Cancer cells themselves are
often the origin of high AGF levels; therefore finding a
dosing strategy that negates this concern could be
important in the elderly AD population.
Conclusions
In summary, our data demonstrate that EGF prevents cog-
nitive decline in female mice that express APOE4 and
overproduce Aβ. Further, there are lower microbleeds and
increased CV coverage but no changes in Aβ levels in
EGF treated mice. Developing therapeutic strategies based
on AGFs could provide alternative therapeutic options for
AD patients.
Additional file
Additional file 1: Figure S1. EGF had no effect on a laminin or b CD31
density (IHC analysis) in E4FADF mice. Data expressed as mean +/− S.E.M.
Data non-significant by Students t test. n = 8 per group. c. Claudin 5 stained
vessels (red) are higher in E4FADF mice after EGF treatment. d Representative
full western blot of EGF receptor levels after EGF or VC treatment (the top
band was quantified). (PDF 2906 kb)
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